Tabula Rasa HealthCare Inc (TRHC) CEO Sells $262,000.00 in Stock
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) CEO Calvin H. Knowlton sold 8,000 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $32.75, for a total transaction of $262,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Tabula Rasa HealthCare Inc (NASDAQ TRHC) traded down $0.11 during mid-day trading on Tuesday, hitting $33.15. 229,576 shares of the stock traded hands, compared to its average volume of 232,217. Tabula Rasa HealthCare Inc has a 1 year low of $11.59 and a 1 year high of $36.80. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.73 and a quick ratio of 0.66. The stock has a market capitalization of $635.88 and a P/E ratio of -195.00.
Tabula Rasa HealthCare (NASDAQ:TRHC) last released its earnings results on Monday, November 6th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Tabula Rasa HealthCare had a negative net margin of 2.27% and a negative return on equity of 5.58%. The firm had revenue of $33.27 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter in the previous year, the firm earned $0.06 earnings per share. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. equities analysts expect that Tabula Rasa HealthCare Inc will post 0.03 EPS for the current fiscal year.
A number of equities analysts have weighed in on the stock. Citigroup assumed coverage on shares of Tabula Rasa HealthCare in a research report on Thursday, January 4th. They issued a “buy” rating for the company. Oppenheimer assumed coverage on shares of Tabula Rasa HealthCare in a research report on Monday, December 18th. They issued an “outperform” rating and a $35.00 price target for the company. BidaskClub lowered shares of Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. ValuEngine upgraded shares of Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research report on Saturday, September 30th. Finally, Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $29.00.
TRADEMARK VIOLATION NOTICE: “Tabula Rasa HealthCare Inc (TRHC) CEO Sells $262,000.00 in Stock” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/01/09/tabula-rasa-healthcare-inc-trhc-ceo-sells-262000-00-in-stock.html.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.